Literature DB >> 20157302

Clinical implications of changing definitions within the Gleason grading system.

Tamara L Lotan1, Jonathan I Epstein.   

Abstract

Remarkably, more than 40 years after the inception of the Gleason grading system, it remains one of the most powerful prognostic predictors in prostate cancer. Gleason's original grading system, however, has undergone significant revision over the years, first by Gleason and his colleagues, and most recently at the 2005 International Society of Urological Pathology Consensus Conference. The consensus conference and subsequent articles proposing further modifications have helped pathologists to adapt the Gleason grading system to current urologic practice in a uniform manner. The changing definitions of Gleason pattern 3 and 4 prostatic adenocarcinoma have tended to narrow the scope of pattern 3 carcinoma and widen the scope of pattern 4 carcinoma. These modifications have had an important role in improving the inter-observer reproducibility of the Gleason system. Whether these changes have a significant impact on the clinical treatment of prostate cancer remains to be seen. However, as many of these modifications are supported only by a few studies, long-term follow-up studies with clinical end points are essential to validate these recommendations.

Entities:  

Mesh:

Year:  2010        PMID: 20157302     DOI: 10.1038/nrurol.2010.9

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  30 in total

1.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist.

Authors:  W C Allsbrook; K A Mangold; M H Johnson; R B Lane; C G Lane; J I Epstein
Journal:  Hum Pathol       Date:  2001-01       Impact factor: 3.466

2.  The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens.

Authors:  Burkhard Helpap; Lars Egevad
Journal:  Virchows Arch       Date:  2006-11-08       Impact factor: 4.064

3.  Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy.

Authors:  Burkhard Helpap; Lars Egevad
Journal:  Anal Quant Cytol Histol       Date:  2008-02       Impact factor: 0.302

4.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

5.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

6.  Histologic grading of primary prostatic cancer: a new approach to an old problem.

Authors:  J F Gaeta; J E Asirwatham; G Miller; G P Murphy
Journal:  J Urol       Date:  1980-05       Impact factor: 7.450

7.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

8.  Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

Authors:  Ofer Yossepowitch; Scott E Eggener; Angel M Serio; Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  Eur Urol       Date:  2007-10-12       Impact factor: 20.096

9.  What are the outcomes of radical prostatectomy for high-risk prostate cancer?

Authors:  Stacy Loeb; Edward M Schaeffer; Bruce J Trock; Jonathan I Epstein; Elizabeth B Humphreys; Patrick C Walsh
Journal:  Urology       Date:  2009-11-22       Impact factor: 2.649

10.  A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.

Authors:  Hiroshi Miyamoto; David J Hernandez; Jonathan I Epstein
Journal:  Hum Pathol       Date:  2009-08-14       Impact factor: 3.466

View more
  14 in total

1.  Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Authors:  Kenneth A Iczkowski; Kathleen C Torkko; Gregory R Kotnis; R Storey Wilson; Wei Huang; Thomas M Wheeler; Andrea M Abeyta; Francisco G La Rosa; Shelly Cook; Priya N Werahera; M Scott Lucia
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

2.  An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.

Authors:  John B Eifler; Zhaoyang Feng; Brian M Lin; Michael T Partin; Elizabeth B Humphreys; Misop Han; Jonathan I Epstein; Patrick C Walsh; Bruce J Trock; Alan W Partin
Journal:  BJU Int       Date:  2012-07-26       Impact factor: 5.588

3.  The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer.

Authors:  Ruprecht Kuner; Maria Fälth; Nicole Chui Pressinotti; Jan C Brase; Sabrina Balaguer Puig; Jennifer Metzger; Stephan Gade; Georg Schäfer; Georg Bartsch; Eberhard Steiner; Helmut Klocker; Holger Sültmann
Journal:  J Mol Med (Berl)       Date:  2012-09-04       Impact factor: 4.599

Review 4.  The evolving Gleason grading system.

Authors:  Ni Chen; Qiao Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 5.  Prostate cancer.

Authors:  Richard J Rebello; Christoph Oing; Karen E Knudsen; Stacy Loeb; David C Johnson; Robert E Reiter; Silke Gillessen; Theodorus Van der Kwast; Robert G Bristow
Journal:  Nat Rev Dis Primers       Date:  2021-02-04       Impact factor: 52.329

6.  Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging.

Authors:  Maria Inês Novis; Ronaldo Hueb Baroni; Luciana Mendes de Oliveira Cerri; Romulo Loss Mattedi; Carlos Alberto Buchpiguel
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Overall and worst gleason scores are equally good predictors of prostate cancer progression.

Authors:  Teemu T Tolonen; Paula M Kujala; Teuvo L J Tammela; Vilppu J Tuominen; Jorma J Isola; Tapio Visakorpi
Journal:  BMC Urol       Date:  2011-10-06       Impact factor: 2.264

8.  Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.

Authors:  Jung Ki Jo; Han Sol Lee; Young Ik Lee; Sang Eun Lee; Sung Kyu Hong
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

9.  The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.

Authors:  Przemyslaw Waliszewski
Journal:  Front Physiol       Date:  2016-02-11       Impact factor: 4.566

10.  Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.

Authors:  K Fizazi; T W Flaig; M Stöckle; H I Scher; J S de Bono; D E Rathkopf; C J Ryan; T Kheoh; J Li; M B Todd; T W Griffin; A Molina; C H Ohlmann
Journal:  Ann Oncol       Date:  2015-11-25       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.